Russell Investments Group Ltd. Has $780,000 Position in Integer Holdings Co. (NYSE:ITGR)

Russell Investments Group Ltd. lessened its position in Integer Holdings Co. (NYSE:ITGR - Free Report) by 76.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,886 shares of the medical equipment provider's stock after selling 19,440 shares during the quarter. Russell Investments Group Ltd.'s holdings in Integer were worth $780,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of ITGR. Mather Group LLC. grew its holdings in shares of Integer by 304.3% in the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 143 shares in the last quarter. Lee Danner & Bass Inc. bought a new position in Integer in the fourth quarter valued at approximately $27,000. R Squared Ltd acquired a new position in shares of Integer during the 4th quarter worth approximately $44,000. Versant Capital Management Inc raised its stake in shares of Integer by 98.4% during the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider's stock worth $49,000 after purchasing an additional 183 shares in the last quarter. Finally, Principal Securities Inc. boosted its holdings in shares of Integer by 31.2% in the 4th quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider's stock valued at $85,000 after buying an additional 152 shares during the last quarter. Institutional investors own 99.29% of the company's stock.

Integer Price Performance

Shares of NYSE ITGR opened at $118.12 on Wednesday. The business's 50 day moving average is $120.73 and its 200-day moving average is $130.42. The firm has a market cap of $4.12 billion, a P/E ratio of 35.16, a price-to-earnings-growth ratio of 1.72 and a beta of 1.09. Integer Holdings Co. has a 1-year low of $104.93 and a 1-year high of $146.36. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62.

Integer (NYSE:ITGR - Get Free Report) last posted its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing analysts' consensus estimates of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The firm had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. Equities research analysts predict that Integer Holdings Co. will post 6.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

ITGR has been the topic of several analyst reports. Oppenheimer lowered shares of Integer from an "outperform" rating to a "market perform" rating in a research report on Friday, February 21st. Raymond James started coverage on shares of Integer in a report on Friday, March 28th. They issued an "outperform" rating and a $145.00 target price on the stock. Truist Financial reduced their price target on Integer from $163.00 to $140.00 and set a "buy" rating for the company in a report on Friday, April 11th. KeyCorp dropped their price objective on Integer from $154.00 to $145.00 and set an "overweight" rating on the stock in a research note on Monday. Finally, Benchmark lifted their target price on Integer from $140.00 to $150.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $145.00.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.